SOPHiA Genetics Jumps on Q2 Beat, AstraZeneca Deal as Volume Spikes
SOPH volume surged to 4.5x average after a Q2 revenue beat and AstraZeneca diagnostics deal, though a wider EPS miss and recent insider selling flag risk in this unclassified-sector name.
signal:SOPH:2026-08-04 SOPHiA Genetics Jumps on Q2 Beat, AstraZeneca Deal as Volume Spikes
Shares of SOPHiA Genetics SA (NASDAQ: SOPH) saw trading volume surge to 4.5x the 20-day average on August 4, 2026, the same day the company reported Q2 revenue that beat estimates and unveiled a global collaboration with AstraZeneca to develop and deploy two companion diagnostics for precision oncology — a combination that makes this a name worth adding to a watchlist even though the underlying loss widened.
| Field | Value |
|---|---|
| Stock name | SOPHiA GENETICS SA |
| Ticker | SOPH |
| Market | NASDAQ |
| Sector | Unclassified |
| Volume (x average) | 4.5x |
| Signal price | $6.84 |
Trade Levels to Monitor
| Level | Price |
|---|---|
| Signal price | $6.84 |
| Stop-loss | $6.16 (-10%) |
| First take-profit | $8.21 (+20%) |
| Trailing stop | 10% from peak, once triggered |
| Invalidation level | $5.77 (close below breaks the thesis) |
What's Driving the Move
The revenue beat, paired with news that AstraZeneca will co-develop companion diagnostics with SOPHiA's platform, appears to be the primary catalyst behind the volume spike rather than any broader sector rotation. Shares rose despite a wider-than-expected loss, suggesting the market is currently pricing the AstraZeneca partnership and revenue trajectory more heavily than near-term profitability.
Risks to Watch
The numbers underneath the headline beat deserve scrutiny. Q2 EPS came in at -$0.26 versus a -$0.2142 estimate, a -21.4% miss on the bottom line even as revenue topped forecasts. EV/EBITDA sits at -5.8x, reflecting that the company is still unprofitable on an operating basis — standard for early-stage diagnostics names but a real risk if the AstraZeneca collaboration takes longer than expected to translate into revenue. Also notable: Form 4 filings show one insider sale and zero insider buys in the past 10 days, a detail worth watching even though a single sale is not conclusive. On the macro side, the backdrop is unusually calm — VIX at 16.5 and US high-yield credit spreads at 2.78%, both in normal ranges — which reinforces that this move looks stock-specific rather than macro-driven, meaning company-level execution risk on the AstraZeneca deal matters more here than index-level volatility.
What to Watch Next
Key things to track from here: whether the AstraZeneca collaboration produces concrete regulatory or commercial milestones, whether insider selling continues or reverses, and whether the stock holds above the $5.77 support level that would otherwise call the current setup into question.
This is a watchlist flag, not a buy signal — SOPH's move from $6.84 toward the $8.21 take-profit zone would confirm the thesis, while a break below the $6.16 stop-loss or the $5.77 invalidation level would suggest the volume surge failed to translate into a durable trend.